-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Lowers Price Target to $11

Benzinga·05/19/2025 11:36:22
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy and lowers the price target from $12 to $11.